PharmTech Drug Digest 11.20
News|Articles|January 6, 2016

UK Pharmaceutical Companies Collaborate on CAR-T Cell Immuno-oncology Therapies

The Cell Therapy Catapult, University of Birmingham, and Cancer Research Technology collaborate on CAR-T cell immuno-oncology therapy development.

Cell Therapy Catapult, University of Birmingham, and Cancer Research Technology announced on Jan. 6, 2016 the launch of a collaboration to develop a new immuno-oncology cellular therapy created modifying the genes of T-cells to target solid tumors.

The project is aimed at translating an academic discovery program into a commercially viable cell therapy. It is funded by Cancer Research United Kingdom (UK) and was developed by Steven Lee, PhD, and Professor Roy Bicknell, both of whom are from the University of Birmingham. The collaborating partners have launched a new company-Chimeric Therapeutics Limited-to manage all future intellectual property rights of any of the resulting discoveries.

The project is based on a new generation chimeric antigen receptor T-cell (CAR-T) immuno-oncology therapy for solid tumors. This involves directing the CAR-T cell towards a new, highly specific marker of tumor angiogenesis, CLEC14a. This therapy will act as a vasculature disruptive agent, compromising oxygen supply to the tumors and inhibiting growth. The technology is currently undergoing the final stages of preclinical development an will enter into clinical trials in the near future.

According to a press announcement from the Cell Therapy Catapult, the company will assist in accelerating the translation of the academic discoveries around CAR-T immunotherapies for solid tumors and the CLEC14a target towards a commercially available cell therapy.

Source: Cell Therapy Catapult


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.